Inclusion Criteria:  Must be ≥ 18 years of age at the time of consent. Initiated or initiating commercially available loncastuximab tesirine treatment. Written informed consent must be obtained prior to any registry activities.  Exclusion Criteria:  Prior loncastuximab tesirine exposure in clinical trials.